ClinicalTrials.Veeva

Menu
E

Erie Retina Research | Erie, PA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Axitinib
Aflibercept
JNJ-81201887
Vamikibart
AVD-104
PL9643
ANX007
RO7446603
BI 771716
BI 836880

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

30 of 39 total trials

4D-150 in Patients With Diabetic Macular Edema

Phase 2 randomized, active-controlled, double-masked, dose-ranging trial in adults with Diabetic Macular Edema (DME).

Enrolling
Diabetic Macular Edema
Diabetic Retinopathy
Biological: Aflibercept IVT
Biological: 4D-150 IVT

A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration

Enrolling
Macular Neovascularization Secondary to Age-Related Macular Degeneration
Biological: 4D-150 IVT (3E10 vg/eye)
Biological: EYLEA® (aflibercept) Injection 2 mg (0.05mL)

This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.

Enrolling
Wet Age Related Macular Degeneration
wAMD
Drug: Aflibercept (2.0 mg)
Drug: EYP-1901

The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ...

Enrolling
Macular Degeneration
Geographic Atrophy
Other: Sham Procedure
Drug: JNJ-81201887

In neovascular (wet) age-related macular degeneration (nAMD), the macula, or the part of the eye that provides the clear, detailed central vision, is...

Invitation-only
Neovascular (wet) Age-related Macular Degeneration (AMD)
Neovascular Age-Related Macular Degeneration (nAMD)
Biological: Aflibercept (2.0 mg)

Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atro...

Active, not recruiting
Macular Degeneration
Geographic Atrophy of the Macula
Drug: AVD-104
Drug: Avacincaptad

This clinical study is designed to demonstrate the equivalence of the two Investigational Products by comparing the efficacy, safety, tolerability an...

Begins enrollment in 1 month
Neovascular Age-related Macular Degeneration (nAMD)
Drug: RBS-001 Solution for intravitreal injection
Drug: Eylea® Solution for intravitreal injection

This is a Phase 3 study to Assess the Efficacy, Safety and Tolerability of OCU400 in patients with retinitis pigmentosa (RP) associated with RHO muta...

Enrolling
Retinitis Pigmentosa
Genetic: Sub-Retinal Administration of OCU400-301

This study will assess corneal endothelial cells in participants with nAMD treated with PDS refilled every 24 weeks (Q24W).

Enrolling
Neovascular Age-related Macular Degeneration
Device: SUSVIMO PDS Implant
Drug: LUCENTIS (ranibizumab injection)

The primary purpose of the study is to determine if IVT injections of ANX007 every month reduce vision loss in participants with GA secondary to age-...

Enrolling
Geographic Atrophy
Drug: ANX007
Other: Sham Administration

In neovascular (wet) age-related macular degeneration (nAMD), the macula, or the part of the eye that provides the clear, detailed central vision, is...

Active, not recruiting
Neovascular (Wet) Age-related Macular Degeneration (nAMD)
Biological: EXG102-031

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

Active, not recruiting
Geographic Atrophy
Drug: Triamcinolone
Other: Sham Procedure

The goal of this clinical trial is to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of VX-01 as stand-alone treatmen...

Enrolling
NPDR - Non Proliferative Diabetic Retinopathy
Diabetic Retinopathy
Drug: VX-01
Drug: Placebo

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (...

Enrolling
Wet Age-related Macular Degeneration
Drug: Tarcocimab tedromer
Drug: Aflibercept

This study will demonstrate that tarcocimab 5 mg is superior to sham treatment in participants with DR.

Active, not recruiting
Diabetic Retinopathy
Drug: Tarcocimab
Other: Sham injection

This study aims to evaluate the ocular and systemic safety, tolerability and efficacy of RO7446603 in participants with diabetic macular edema (DME)....

Enrolling
Diabetic Macular Edema
Drug: Faricimab
Drug: Aflibercept

This study will assess the efficacy and safety of vamikibart in participants with uveitic macular edema.

Active, not recruiting
Uveitic Macular Edema
Other: Sham
Drug: Vamikibart

The study consists of a randomized double-masked, placebo-controlled, parallel-group, multicenter trial with an optional open-label treatment period...

Enrolling
Thyroid Eye Disease
Other: Placebo
Biological: Teprotumumab

The goal of this clinical trial is to assess the efficacy and safety of multiple doses of foselutoclax (UBX1325) in patients with Diabetic Macular Ed...

Active, not recruiting
Edema
Diabetic Macular Edema
Drug: foselutoclax
Drug: Aflibercept

A study to evaluate the safety and efficacy of YUTIQ® 0.18 mg intravitreal implant for the management of chronic non-infectious posterior segment uve...

Active, not recruiting
Uveitis, Posterior
Drug: Fluocinolone Acetonide Intravitreal Implant 0.18 mg

Trial sponsors

Boehringer Ingelheim logo
Ocugen logo
4
A
E
Genentech logo
Janssen (J&J Innovative Medicine) logo
Kodiak Sciences logo
Ocular Therapeutix logo
Roche logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems